species (5), by both liver and plasma esterases. MPA is a potent and specific inhibitor of de no6o purine synthesis. As a result of this inhibition, the proliferation of both T and B lymphocytes is blocked (6) and antibody production is inhibited (7, 8) . MPA, in turn, is almost completely metabolized to form the phenolic glucuronide of MPA (MPAG), which is not pharmacologically active (6) .
An intravenous (i.v.) formulation of MMF has been recently released. The availability of such a formulation enables MMF to be administered to patients unable to tolerate oral medication. Following intravenous administration, MMF is also rapidly hydrolyzed with a half life of only a few minutes to MPA (5) . In pharmacokinetic (PK) studies, i.v. MMF has been administered to normal volunteers (9) and to a limited number of renal and hepatic transplant recipients in the immediate postoperative period. When given to normal individuals, C max was higher (47.290.3) after i.v. dosing than oral dosing (34.09 7.1). The MPA area under the concentration curve (AUC) from time 0 to 24 h was significantly higher following i.v. administration compared to per os (p.o.) administration, but the total AUC was statistically equivalent. T max was similar (9, 10) . Unpublished data from a small open-labeled study of the pharmacokinetics of MMF (1.5 g twice daily [b.i.d.]) p.o., or i.v. infusions of 1 or 3 h in duration, or as a continuous infusion to renal allograft recipients showed that: the MPA AUC values were relatively independent of the infusion time (1); the interdosing-interval MPA AUC values were comparable for the same i.v. and p.o. dose of MMF (2) ; and that the MPA C max values were inversely related to infusion time (3) . From the C max data obtained, it was estimated that an i.v. MMF dose of 1 g b.i.d. administered over 2 h was likely to result in peak plasma MPA concentrations comparable to those following administration of the same dose of p.o. MMF. These data formed the basis for the dosing schedule employed in the present study.
The present study analyzes the results of two related studies (MYCS2172 and MYCS2734) in de no6o renal transplant patients in the immediate postoperative period. Only a single dose level of i.v. MMF (1 g b.i.d.), the dose of MMF currently recommended for renal transplant recipients, was studied. The PK study (MYCS2734) was designed primarily to compare the bioavailability and pharmacokinetics of MPA after multiple i.v. dosing when switching to p.o. capsules. The design of the safety study allowed an unbiased comparison of the safety of the two methods of administration.
Patients and methods
Both studies were approved by the institutional review boards at each center. Written informed consent was obtained and the patients were screened for eligibility within 48 h prior to transplantation. Patients were eligible if they were: recipients of a first or second renal transplant (single-organ transplant only); at least 18 yr of age; able to receive p.o. and i.v. medication. Patients were excluded if: they were pregnant or nursing; had severe diarrhea or other gastrointestinal (GI) disorders; had active peptic ulcer disease; if the patient or the donor had serologic evidence of HTLV-1, HIV, or HbsAg; had a malignancy or history of malignancy; had a systemic infection; had a white blood cell count less than 2500/mm 3 , a platelet count less than 100000/mm 3 , or hemoglobin less than 6 g/dL at the time of entry; required concomitant therapy with azathioprine, tacrolimus, rapamycin, or any investigational drug. Antacids were not permitted during the PK study. Patients who fulfilled the inclusion/exclusion criteria were enrolled into the respective studies prior to transplantation.
The safety and tolerability study was a randomized, multicenter, double-blind study (for the first 5 d, with an open-labeled follow-up) parallel group design. Before transplantation, eligible patients were randomized in a 2:1 ratio to groups designated 'MMF i.v. study drug was begun as soon as the patient could take the study capsules, but must have been started within 72 h after transplantation. Patients completed the study on study day 21. Subsequent therapy was determined by the patient's physicians. The PK study was also a multicenter one. It was open-labeled with only one treatment group. Treatment with i.v. MMF began within 24 h after transplantation, followed by a switch to p.o. MMF on the evening of day 5. Patients completed the study on day 6.
The MMF used for i.v. administration was supplied as a lyophilized powder in glass vials containing the equivalent of 500 mg of MMF (542 mg of MMF hydrochloride), polysorbate 80, and anhydrous citric acid. A matching placebo for i.v. MMF contained 250 mg mannitol, 120 mg dextrose, polysorbate 80, riboflavin, and anhydrous citric acid. The pharmacist at each study site reconstituted and prepared each dose of i.v. study drug. The i.v. solution was prepared and administered within 12 h of reconstitution. The i.v. solution of MMF or placebo was administered, if possible, via a dedicated peripheral venous catheter cleared with D5W prior to infusion of the study drug. A central line could be used if a peripheral line could not be established or if local irritation developed. The i.v. solutions were infused via a pump at a rate of 84 mL/h for 2 consecutive hours. Other drugs were not to be given simultaneously with MMF through the infusion line or mixed in the infusion bag. If possible, in order to permit a more accurate assessment of the local tolerance of MMF, other drugs were not to be administered at any time through the peripheral i.v. line for MMF. Peripheral infusion sites were changed every 72 h.
The MMF and placebo used for oral administration were supplied in blue, opaque, size c 1 capsules. MMF capsules contained 250 mg MMF, pregelatinized starch, croscarmellose sodium, povidone (K-90), and magnesium stearate. Placebo capsules contained pregelatinized starch, croscarmellose sodium, (K-90), and magnesium stearate.
The first day on which the patient received an AM dose of i.v. study drug was designated as study day 1. If the first dose of i.v. study drug was administered PM, this day was designated as study day 0. Subsequent doses of i.v. study drug were given every 12 h through, and including, the morning or the evening of day 5 for the PK and safety studies, respectively. For the safety study, the patients received a total of either 10 or 11 i.v. doses of blinded study drug, depending on whether the first dose was administered on study days 1 or 0, respectively. For the PK study, the patients received a total of either 9 or 10 i.v. doses of open-labeled i.v. MMF, depending on whether the first dose was administered on study days 1 or 0, respectively.
For the safety study, the first dose of oral study drug was administered as soon as the patient could take the capsules. Once oral dosing was initiated, patients received their study capsules at the same time as the start of their i.v. infusions for the remainder of the double-blind phase of the study. Four capsules of oral study drug were administered b.i.d., to be swallowed intact. Open-label MMF capsules were administered (1 g b.i.d.) on study days 6 through 21. During the blinded phase of the safety study (study days 0/1 through 5), no modification of the dose of i.v. or p.o. study drug was allowed. During the open-labeled oral dosing phase (study days 6 through 21), if an adverse event (AE) occurred the dose of MMF could be reduced or interrupted as deemed appropriate by the investigator.
For the PK study, p.o. MMF was administered on the evening of day 5 and the morning of day 6. No modification or interruption of the dose of i.v. or p.o. study drug was allowed. If a patient missed any doses of i.v. or p.o. MMF or was unable to take four MMF capsules by the evening of study day 5, the patient was excluded from the PK evaluation.
The safety study was designed to make direct comparisons between the two treatment groups during the double-blind period. Since AEs occurred between the time of the first i.v. dose (i.e., placebo) and the first dose of p.o. MMF for patients randomized to the p.o. MMF 2 g/d group, patients were declared 'on treatment' at the time they received their first i.v. placebo dose, so that inspection of data for 'delayed' AEs was possible. The summary of AEs -by treatment groupcollected while the patients were on double-blind i.v. treatment included all AEs with onset date/ time on or after the date/time of the first i.v. infusion up to the date/time of the first open-labeled oral dose. The summary of AEs during the 21 d of study included all AEs that occurred on the day of the first dose of study drug up through the first 21 d on study, and excluded all AEs that occurred after the termination date for those patients prematurely terminating from the trial. The summary of patients with AEs probably or possibly related to the study drug used the relationship as reported by the investigator, and also included AEs for which the relationship was missing. All opportunistic infections (OIs) were included in this summary. Particular attention was paid to the peripheral i.v. infusion sites, that were inspected on study days 0/1, 2, 3, 4, and 5. Beginning immediately prior to and continuing for 2 h after the end of the initial infusion of study drug, patients were monitored utilizing continuous electrocardiogram (ECG), noninvasive arterial oxygen saturation (SaO 2 ), and supine blood pressure and pulse rates obtained at 30-minute intervals. Pulse rates and supine blood pressure were also recorded prior to, 30 min after the start, and at the completion of the AM i.v. administration of study drug on study days 3 and 5.
For the PK study, the primary objective was to compare MMF bioavailability, determined by the MPA AUC 0-12 , when switching from the 2-h i.v. infusion on study day 5 to the 250-mg capsule dosage form on study day 6. Patients fasted (water permitted) overnight, beginning at 10 PM on the nights prior to study days 5 and 6. Blood samples (5 mL each) for the measurement of MPA and MPAG were obtained from either a peripheral or a central line using a port dedicated to drawing blood samples or by venipuncture. If MMF was administered through a peripheral vein, blood samples were not taken from the limb in which the infusion was administered. If MMF was administered through a central line, blood samples were obtained from a peripheral vein. Blood samples were collected in heparinized tubes immediately before dosing (at 0 minutes), at 20, 30, 40, 60, 80, 100, 120, 140, and 160 min, and at 3, 4, 6, 8, and 12 h after the AM dose on study days 5 and 6.
Plasma samples were analyzed for MPA and MPAG concentrations by high-performance liquid chromatography (PHARMout Laboratories, Sunnyvale, CA). The limit of quantitation for MPA in plasma was 0.1 mg/mL. The limit of quantitation for MPAG in plasma was 4.0 mg/mL (2.38 mg/mL in MPA-equivalent units). Actual times were used in the calculation of all computed PK parameters. AUC was calculated using the linear trapezoidal rule. C max was determined by visual inspection of the data, and T max was determined to be the time at which it occurred. All MPAG concentrations were expressed in MPA-equivalent units by multiplying all reported MPAG concentrations by the ratio of MPA molecular weight to MPAG molecular weight (320.35/539.42). Concentrations below the limit of quantitation of the assay were treated as 0 in statistical summaries.
Statistics
For the safety study, the sample size was selected empirically without formal assessment of study power. All patients enrolled in the trial who received at least one dose of study drug were included in the assessment of safety. All safety data were summarized using descriptive statistics. For each patient, multiple or repeated AEs that mapped to a common preferred term were condensed to a single AE.
No hypothesis testing was performed for efficacy because of the short duration of the study and the relatively small sample size. The number of full or partial courses of immunosuppressives for the treatment of rejection during the study was summarized. A full course was at least 1 d of anti-thymocyte globulin (ATG), or ALG, or anti-CD3 rnAb (OKT3), or corticosteroids administered for at least 3 d with a total course dose of 600 mg or more. A partial course was corticosteroids administered for 2 d or less, regardless of dose, or a total dose of less than 600 mg at an average daily dose of at least 100 mg.
For the PK study, the planned enrollment was 40 patients, with the expectation that at least 24 patients would be evaluable. Although this was not a formal crossover bioequivalence study, the goal of 24 evaluable patients was based on bioequivalence criteria, assuming an intra-subject percentage coefficient of variation of 22.5 for log-transformed AUC 0-12 ln(AUC 0-12 ) (based on a previous unpublished study), with 80% power to show bioequivalence -assuming a difference of no more than 5% between the two routes of administration. The computed parameters were analyzed using ANOVA with terms for patient and route of administration. Statistical analyses were performed using SAS, version 6.09. Ordinary confidence intervals (CIs; 90% and 95%) for the difference in least squares means were constructed and expressed as a percentage (i.v. relative to p.o.) to compare the bioavailability of the two routes of administration.
Results

Safety study
One-hundred and sixty patients (n=104 i.v.-p.o., and n=56 p.o.-p.o.) qualified to enter the safety study. Twenty-eight patients were prematurely terminated from the study. Seven patients, 6 in the MMF i.v.-p.o. group and one in the MMF p.o.-p.o. group, were randomized but never received study drug and were not evaluated for safety. Of these, 4 patients did not receive their transplant. Two patients changed their mind about participating in the study. Fifteen patients prematurely terminated from the trial because of AEs: 11 patients (11%) in the i.v.-p.o. group and 4 patients (7%) in the p.o.-p.o. group. These cases are discussed below. One patient received 3 g/d of MMF to treat a rejection episode. Three patients were terminated because they received prohibited medications (OKT3, tacrolimus, and tacrolimus, respectively). One patient was terminated after 16 d because the physician considered him to be over-immunosuppressed. One patient terminated for personal reasons after having received the study drug for 15 d, and one other for non-compliance.
Selected demographics of the 153 evaluable patients are summarized ( 
For the 153 patients who received study medication, Fig. 1 displays all specific AEs that occurred in at least 20% of patients from the time of the first dose of i.v. study medication until the time the patient was placed on open-labeled p.o. MMF or was terminated from the study (i.e., prematurely terminated treatment during the i.v. phase of the study). All but one patient (MMF i.v.-p.o. group) experienced at least one AE during the doubleblind i.v. phase of the study. With the exception of hypophosphatemia, these AEs, as well as those reported for B20% of patients, were fairly evenly distributed between the two treatment groups. A small excess of cardiovascular events (chiefly ECG abnormalities) were reported in the MMF i.v.-p.o. group (not shown). These were without hemodynamic consequences (e.g., arrhythmia, atrial fibrillation/flutter, and bigeminy).
In ripheral infusion reported a peripheral infusion-site reaction (Fig. 2) . Venous thrombosis (4 patients, 4.1%), phlebitis, and hemorrhage were only reported in the MMF i.v. -p.o. group. Only 1 patient (MMF p.o.-p.o. group) was terminated from the study for a peripheral infusion-site reaction (infusion-site infiltration and edema). Table 2 AEs were fairly evenly distributed between the two treatment groups.
Ten percent of all evaluable patients (15/153) prematurely terminated study treatment because of AEs. These included 11% (11/98) of patients in the MMF i.v.-p.o. group and 7% (4/55) patients in the MMF p.o.-p.o. group. Only two patients in the i.v.-p.o. group terminated during the doubleblind phase; one for atrial fibrillation and thrombosis, and the second for increased liver enzymes (serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase to 341 IU/L and 425 IU/L, respectively). Likewise, only 3 patients in the p.o. -p.o. group terminated during the double-blind phase; 2 for nausea and vomiting and 1 for injection site reaction.
Pulse rate and systolic and diastolic blood pressure results showed no difference either within or between groups when comparing baseline (pre-infusion) measurements with those taken every 30 min for 4 h after the first dose of i.v. study drugs, or between baseline measurements and those taken after 30 minutes and at the end of the AM infusions on study days 3 and 5 (not shown). Similarly no differences were observed in results from continuous ECG and arterial oxygen saturation monitoring for 4 h after the first dose of i.v. study drugs (not shown).
Seven percent of all evaluable patients (10/153) developed an opportunistic OI (Table 3) PK study A total of 45 patients from eight centers qualified to enter the PK study. All patients enrolled into this study received their transplants and at least one dose of study drug. The demographics for the patients in the PK study were similar to the double-blind safety study (data not shown). Three patients who completed the study normally were not evaluable for pharmacokinetics because of problems with blood sampling. Eleven patients did not complete the PK study because of AE (n=5), unsatisfactory therapeutic response (rejection, n= 1), prohibited medication (use of tacrolimus, n= 1), and other reasons (n=4, 3 for dialysis). The safety profile was similar to that seen with the double-blind study (data not shown).
Thirty-one patients were evaluable for the PK analyses. Statistically significant differences in mean plasma MPA concentration between the i.v. and p.o. routes of administration were observed for the 0.33-, 0.67-, 1.0-, 1.33-, 1.67-, 2.0-, and 2.33-h time points (Fig. 3) . Statistically significant differences between the routes were observed for AUC 0-12 (p B0.001) but not C max (p =0.252) ( Table 5 ). The apparent discrepancy between the C max seen in Fig. 3 and the C max in Table 5 results from the method of calculating the respective results. In Fig. 3 , the data are the average of the individual results at each defined time point. In Table 5 , the C max is the average of the individual C max , regardless of the time at which it occurs. The ordinary CIs (90%) for the difference in least squares means were constructed and expressed as a percentage (i.v. relative to p.o.) for the computed parameters AUC 0-12 C max and T max ( Table 5 ). The percentages for AUC 0-12 and C max fall outside the 80-120% (non-transformed) or 80-125% (logtransformed, not shown) bounds required to conclude that the formulations were bioequivalent. The ratio for ln(AUC 0-12 ) was 129% (90% CI of 119-139%) while that for ln(C max ) was 120% (90% CI of 101-143%). No statistically significant difference between the i.v. and p.o. routes of administration was observed for mean plasma MPAG concentrations at any time point (Fig. 4) , or for MPAG AUC 0-12 and C max ( Table 5) . As opposed to the findings with MPA, the ordinary CIs (90 and 95%) for the difference in least squares means for both AUC 0-12 and C max fell within the 80 -120% (non-transformed) or 80-125% (log-transformed) bounds for bioequivalence (not shown).
Discussion
Overall, the AE experience of patients receiving i.v. MMF in the safety study (and confirmed in the smaller open-labeled PK study) appeared to be comparable to those receiving i.v. placebo during both the 5-day, double-blind i.v. phase of the study and the open-labeled oral follow-on phase. The overall incidence of local site reactions of peripherally administered infusions appeared to be unrelated to treatment with either i.v. MMF or placebo. However, the peripheral i.v. infusion of MMF appeared to be associated with a higher incidence of local edema and inflammation. Injection site hemorrhage, phlebitis, and thrombosis were observed only in the MMF i.v. -p.o. treatment group, and may be caused by the i.v. MMF formulation. Although none of these events resulted in the interruption or discontinuation of i.v. administration of MMF, a central venous line for infusion may be a preferred alternative, if available. However, with the overall low incidence of infusion-site complications, it is probably not worth placing a central line solely for the administration of i.v. MMF.
The difference in edema rates for the period up to 21 d may be associated with overall differences in the characteristics of the two groups that were reflected in other measures of renal function. It is improbable that this apparent post-i. (Fig. 3) , however, is nearly identical to that follow- ing p.o. dosing, indicating that a 2-h infusion nearly mimics p.o. dosing. Based on the known PK/PD relationship for MPA AUC, it is anticipated that a 1 g i.v. dose of MMF administered twice daily according to the above regimen will provide efficacy at least as good as p.o. treatment (11) . Shaw et al. (12) , using p.o. MMF, reported that renal transplant recipients with an average MPA AUC of 40.9 mg·h/mL (similar to that seen in this study with i.v. administration) had a rejection rate of 8.5%, which was considerably less than the 25.5% rate seen with an AUC of 22.1 mg·h/mL. With an AUC of 64.2 mg·h/mL the rejection rate was decreased even further to 5.8%.
Despite the greater drug exposure, the safety profile was comparable, at least over the short term. It is uncertain if there will be an advantage to using higher doses of i.v. MMF (e.g., 1.5 g b.i.d.) in high risk groups or if this will lead to increased toxicity. From a safety perspective, the i.v. form of MMF (1 g administered over 2 h, given twice daily) provides an acceptable alternative dose form to p.o. MMF in those patients unable to take p.o. medication.
